» Articles » PMID: 33126875

New Strategies of Physical Activity Assessment in Cystic Fibrosis: a Pilot Study

Overview
Journal BMC Pulm Med
Publisher Biomed Central
Specialty Pulmonary Medicine
Date 2020 Oct 31
PMID 33126875
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Regular physical activity (PA) is a valued part of cystic fibrosis (CF) care. Although the accelerometer, SenseWear Armband (SWA), accurately measures habitual PA in CF, it is mostly used for research purposes. For the first time, we analyzed different methods of measuring PA in daily life by the use of smartphones and other electronic devices such as smartwatch and Fitbit.

Methods: Twenty-four stable adults with CF (mean age 37.5 ± 11.5SD yrs.; FEV 58 ± 19% predicted, BMI 22.9 ± 3.2) were studied. Daily PA was monitored for seven consecutive days. All patients wore the accelerometer SWA and at the same time they monitored PA with the electronic device they used routinely. They were allocated into one of four arms according to their device: Smartwatch, Fitbit, Android smartphones and iOS smartphones. PA related measurements included: duration of PA, energy expenditure, number of steps.

Results: There was a good agreement between SWA and Fitbit for number of steps (p = 0.605) and energy expenditure (p = 0.143). iOS smartphones were similar to SWA in monitoring the number of steps (p = 0.911). Significant differences were found between SWA and both Smartwatch and Android smartphones.

Conclusions: Fitbit and iOS smartphones seem to be a valuable approach to monitor daily PA. They provide a good performance to measure step number compared to SWA.

Citing Articles

Telemedicine and Its Application in Cystic Fibrosis.

Fainardi V, Capoferri G, Tornesello M, Pisi G, Esposito S J Pers Med. 2023; 13(7).

PMID: 37511654 PMC: 10381340. DOI: 10.3390/jpm13071041.

References
1.
Kosma M, Cardinal B, McCubbin J . A pilot study of a web-based physical activity motivational program for adults with physical disabilities. Disabil Rehabil. 2006; 27(23):1435-42. DOI: 10.1080/09638280500242713. View

2.
Moorcroft A, Dodd M, Webb A . Exercise testing and prognosis in adult cystic fibrosis. Thorax. 1997; 52(3):291-3. PMC: 1758504. DOI: 10.1136/thx.52.3.291. View

3.
Conn V, Hafdahl A, Brown S, Brown L . Meta-analysis of patient education interventions to increase physical activity among chronically ill adults. Patient Educ Couns. 2007; 70(2):157-72. PMC: 2324068. DOI: 10.1016/j.pec.2007.10.004. View

4.
Crapo R, Morris A, Gardner R . Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis. 1981; 123(6):659-64. DOI: 10.1164/arrd.1981.123.6.659. View

5.
Savi D, Schiavetto S, Simmonds N, Righelli D, Palange P . Effects of Lumacaftor/Ivacaftor on physical activity and exercise tolerance in three adults with cystic fibrosis. J Cyst Fibros. 2019; 18(3):420-424. DOI: 10.1016/j.jcf.2019.03.001. View